June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
A Phase 3 Clinical Study to Evaluate the Efficacy and Safety of Fixed Combination of Azithromycin and Dexamethasone in DuraSite, and Dexamethasone alone in DuraSite in the Treatment of Blepharitis
Author Affiliations & Notes
  • Kamran Hosseini
    Clinical, InSite Vision Inc, Alameda, CA
    KMG Pharma, Mountain View, CA
  • Richard Lindstrom
    Minnesota Eye Consultants, Bloomington, MN
  • Footnotes
    Commercial Relationships Kamran Hosseini, InSite Vision, Inc (E); Richard Lindstrom, InSite Vision, Inc (C)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 3058. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Kamran Hosseini, Richard Lindstrom; A Phase 3 Clinical Study to Evaluate the Efficacy and Safety of Fixed Combination of Azithromycin and Dexamethasone in DuraSite, and Dexamethasone alone in DuraSite in the Treatment of Blepharitis . Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):3058.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To evaluate the efficacy and safety of the combination and single agents, dexamethasone and azithromycin in DuraSite vehicle (AzaSite). The study was also designed to investigate disease response to therapy in combination with lid hygiene using lid scrubs. Furthermore, the recurrence rate of the disease was to be investigated during a 6 month follow up period.

Methods: In this randomized, double masked, multicenter, 4-arm, parallel-group, comparative study subjects received: dexamethasone-azithromycin combination (n=305), dexamethasone (n=298), AzaSite (n=155), or DuraSite Vehicle (n=149). Subjects started the study with a weeklong lid hygiene regimen followed by the application of 1 drop of study medication onto the eyelid(s) twice a day for 14 days. Subjects were assessed on Day 4 during the 2-week dosing period, and at day 15 and Month 1, 2, 3, 4, 5, and 6 during the 6 month post-treatment evaluation phase.. The clinical signs (eyelid redness, eyelid swelling, lid-debris) and eyelid irritation were evaluated. Furthermore, a Patient Report Outcome instrument designed in collaboration with UCLA and FDA was employed to assess the patient’s satisfaction level during the study.

Results: Subjects randomized to the dexamethasone-azithromycin combination arm and dexamethasone arm had a statistically significantly (p < 0.05) greater reduction in blepharitis scores when compared to AzaSite and/or Vehicle arms. The proportion of subjects with the eyelid irritation score of 0 at Day 15 were significantly (p < 0.05) higher in those dexamethasone containing arms as well. Adverse events were reported in approximately 26% of the patients, with an equal distribution among the corticosteroid containing and Vehicle arms, with approximately 21% in the AzaSite arm. Intraocular pressure increase was observed in the combination (2%), dexamethasone alone (1%), and AzaSite (1.3%) arms.

Conclusions: The potent anti-inflammatory properties of dexamethasone formulated in the long lasting DuraSite vehicle appear to be efficacious in treating these important signs and symptoms of blepharitis, which was maintained for up to 6 months for a vast majority of the patients. Additionally, no significant safety findings were reported.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×